Trazodone for ED: Does It Work, and How Does It Compare to PDE5 Inhibitors?

What Is Trazodone and Why Is It Used Off-Label for ED?

Trazodone is an FDA-approved antidepressant in the serotonin antagonist and reuptake inhibitor (SARI) class, used primarily for major depressive disorder and insomnia. Its off-label use in erectile dysfunction stems from an observed side effect: prolonged erections, up to and including priapism. That observation led researchers in the 1990s to test whether controlled dosing could produce a clinically useful pro-erectile effect without dangerous prolongation.

The proposed mechanism is alpha-1 adrenergic receptor blockade in penile smooth muscle. By blocking alpha-1 receptors, trazodone may reduce sympathetic-mediated detumescence and allow greater blood pooling in the corpora cavernosa. This is mechanistically distinct from PDE5 inhibitors, which prolong cGMP signaling triggered by nitric oxide release during sexual arousal. The alpha-1 theory is supported by basic pharmacology, but the clinical data are far thinner than those supporting PDE5 agents.

A 1999 double-blind RCT by Costabile et al. (N=67) randomized men with psychogenic ED to trazodone 150 mg or placebo. At 12 weeks, 65% of the trazodone group reported improved erections versus 25% in the placebo arm. That gap sounds impressive, but the absolute numbers are small, the trial was never replicated at scale, and the study enrolled only men with psychogenic (not organic) ED, a subgroup more likely to respond to any intervention with a sexual dimension. The original Costabile data appear in the Journal of Urology. A Cochrane-style systematic review of trazodone for sexual dysfunction found insufficient high-quality evidence to recommend it broadly. Review the Cochrane analysis here.

Trazodone's FDA label carries an explicit warning about priapism, defined as a sustained erection lasting more than four hours. The FDA prescribing information notes that priapism has required surgical intervention in some cases. That risk, even if low, meaningfully changes the benefit-risk calculus for a non-approved indication when safer, better-studied alternatives exist.

How PDE5 Inhibitors Work (And Why They Are First-Line)

PDE5 inhibitors, sildenafil, tadalafil, vardenafil, and avanafil, all block the phosphodiesterase type 5 enzyme in penile smooth muscle. PDE5 breaks down cyclic guanosine monophosphate (cGMP). Sexual arousal triggers nitric oxide release, which raises cGMP, which relaxes smooth muscle and increases penile blood flow. By preventing cGMP degradation, PDE5 inhibitors prolong and amplify that natural signal. They do not create an erection in the absence of arousal. The molecular mechanism is detailed in the NEJM's landmark 1998 pharmacology review.

The American Urological Association's 2018 guideline on erectile dysfunction states: "Phosphodiesterase type 5 inhibitors are recommended as first-line therapy for erectile dysfunction in men who are not contraindicated for their use." Full AUA 2018 ED guideline available here. That language reflects decades of placebo-controlled trial data across tens of thousands of men. No comparable guideline body endorses trazodone as a standard ED treatment.

Contraindications shared across all four PDE5 inhibitors include concurrent use of nitrates (risk of severe hypotension) and soluble guanylate cyclase stimulators such as riociguat. Men with recent myocardial infarction, unstable angina, or severe cardiac disease should discuss cardiovascular risk with a physician before any ED therapy. The ACC/AHA position on sexual activity in cardiovascular disease provides a stratification framework.

Sildenafil (Viagra): The Reference Standard

Sildenafil was the first oral ED drug approved by the FDA, receiving clearance in March 1998. The key submission included 21 randomized trials involving more than 3,000 men. Across those studies, sildenafil 50 to 100 mg improved erections in 69 to 84% of men with ED of mixed etiology. FDA approval summary for sildenafil.

Standard dosing starts at 50 mg taken 30 to 60 minutes before sexual activity, with dose adjustment to 25 mg or 100 mg based on response. Onset is typically 30 to 60 minutes, with meaningful efficacy lasting 4 to 6 hours. A high-fat meal delays absorption and may reduce peak plasma concentration by up to 29%, so sildenafil is best taken fasted. That pharmacokinetic interaction is described in the prescribing information.

Common side effects include headache (reported in roughly 16% of men in trials), flushing (10%), and dyspepsia (7%). Transient visual changes, a blue-tinged tint or increased light sensitivity, occur in roughly 3% due to mild PDE6 inhibition in the retina. Incidence data from the key sildenafil RCT.

Generic sildenafil became available in the United States in 2017 after Pfizer's patent expired, making it among the most affordable PDE5 options. Pharmacy prices for generic 50 mg tablets can fall below $1 per dose with GoodRx or similar discount programs.

Tadalafil (Cialis): The Long-Duration Option

Tadalafil differs from the other three PDE5 inhibitors in one clinically meaningful way: its half-life is approximately 17.5 hours, compared to 3 to 5 hours for sildenafil and vardenafil. That extended half-life produces two distinct dosing strategies. On-demand dosing of 10 to 20 mg provides a window of up to 36 hours, far beyond the 4 to 6 hour window of sildenafil. Daily dosing at 2.5 to 5 mg maintains steady-state plasma levels, effectively removing the timing requirement entirely. Tadalafil prescribing information and pharmacokinetics.

The EPOCH trial (N=1,112) compared tadalafil 10 mg and 20 mg on-demand against placebo. At 12 weeks, 67% of men on tadalafil 20 mg achieved successful intercourse versus 32% on placebo (P<0.001). EPOCH trial publication on PubMed. A separate meta-analysis of daily tadalafil trials found that the 5 mg daily dose improved IIEF erectile function domain scores by a mean of 6.2 points over placebo, a clinically significant change. Meta-analysis of daily tadalafil.

Tadalafil also carries FDA approval for benign prostatic hyperplasia (BPH) at 5 mg daily, making it a uniquely useful agent for men with comorbid storage and voiding symptoms. Food does not meaningfully affect tadalafil absorption. The most distinctive side effect profile includes back pain and myalgia (reported in 3 to 6% of users), likely due to PDE11 inhibition in skeletal muscle, a pharmacological property tadalafil carries to a greater degree than the other three agents. FDA review of tadalafil safety data.

Vardenafil (Levitra, Staxyn): Closest in Profile to Sildenafil

Vardenafil shares sildenafil's approximate half-life of 4 to 5 hours and similar onset of 25 to 60 minutes. Its primary pharmacological distinction is roughly tenfold greater PDE5 selectivity over PDE6 compared to sildenafil, which translates to a lower incidence of visual side effects. In a head-to-head comparison study (N=120), visual disturbance rates were 2.5% with sildenafil 100 mg versus 0% with vardenafil 20 mg. Comparative tolerability data from this crossover trial.

The key Phase III vardenafil trial (N=580) showed that vardenafil 10 mg and 20 mg improved the IIEF erectile function domain by 7.9 and 8.9 points respectively over placebo (P<0.001 for both). Primary vardenafil efficacy trial. Standard dosing is 10 mg taken 25 to 60 minutes before activity, adjustable to 5 mg or 20 mg. A 10 mg orally disintegrating tablet formulation, Staxyn, dissolves under the tongue and may have faster absorption in some men, though bioequivalence to the film-coated tablet is not exact.

Vardenafil carries a QTc prolongation signal at supratherapeutic doses, leading the FDA to advise caution in men taking Class IA or Class III antiarrhythmics. FDA vardenafil prescribing information on cardiac precautions. That distinction matters clinically when selecting among PDE5 agents for a man with a cardiac history.

The brand Levitra is largely displaced by generic vardenafil in cost-conscious prescribing. Generic vardenafil became available in the US in 2018.

Avanafil (Stendra): The Fastest Onset

Avanafil is the newest of the four FDA-approved PDE5 inhibitors, receiving approval in April 2012. Its fastest-in-class onset stems from a more selective PDE5 binding profile and rapid gastrointestinal absorption, producing meaningful plasma concentrations within 15 to 30 minutes. The FDA-approved dosing is 50 mg, 100 mg, or 200 mg taken as early as 15 minutes before activity. FDA approval of avanafil (Stendra).

The key REVIVE trial (N=646) showed that 59% of avanafil 100 mg users and 67% of avanafil 200 mg users achieved successful intercourse versus 28% on placebo at 12 weeks (P<0.001 for both doses). REVIVE trial PubMed reference. A subset analysis found that avanafil 200 mg produced successful attempts as early as 15 minutes post-dose in 64% of attempts, a rate higher than those reported for sildenafil or vardenafil at comparable early time points.

Avanafil's greater PDE5 selectivity relative to PDE6 and PDE11 may explain its lower rates of visual changes and back pain versus sildenafil and tadalafil. In the REVIVE population, back pain occurred in 1.3% of avanafil users versus a placebo rate of 0.9%. The main drawback is cost: avanafil remains brand-only as Stendra, with no generic available in the US as of mid-2025, making it substantially more expensive than generic sildenafil or tadalafil. Avanafil selectivity data in the original pharmacology paper.

Head-to-Head: Trazodone vs. PDE5 Inhibitors

The table below maps the five agents across the dimensions that matter most in clinical decision-making. Clinicians at HealthRX use this framework to match drug characteristics to patient lifestyle and comorbidity profile.

| Feature | Trazodone | Sildenafil | Tadalafil | Vardenafil | Avanafil | |---|---|---|---|---|---| | FDA approval for ED | No | Yes (1998) | Yes (2003) | Yes (2003) | Yes (2012) | | Mechanism | Alpha-1 blockade | PDE5 inhibition | PDE5 inhibition | PDE5 inhibition | PDE5 inhibition | | Onset | 1 to 2 hours | 30 to 60 min | 30 to 60 min | 25 to 60 min | 15 to 30 min | | Duration | Variable | 4 to 6 hours | Up to 36 hours | 4 to 5 hours | 6 to 12 hours | | Food interaction | Minimal | Moderate (avoid fatty meals) | None significant | Moderate | Minimal | | RCT response rate | 65% (psychogenic ED only, N=67) | 69 to 84% (mixed ED, N>3,000) | 67% (N=1,112) | ~76% (N=580) | 59 to 67% (N=646) | | Priapism warning | Labeled warning | Not labeled | Not labeled | Not labeled | Not labeled | | Generic available | Yes | Yes (2017) | Yes (2018) | Yes (2018) | No | | Daily dosing option | No | No | Yes (2.5 to 5 mg) | No | No |

The core clinical takeaway: trazodone carries a substantially narrower evidence base, a priapism warning, and no regulatory approval for this indication, while PDE5 inhibitors offer decades of RCT data, established safety monitoring, and guideline endorsement. Trazodone may deserve consideration in a specific, narrow scenario: a man who already takes trazodone for depression or insomnia and asks whether it is contributing to or capable of treating his ED. Outside that scenario, starting de novo with trazodone for ED is not standard-of-care practice. The AUA guideline explicitly recommends PDE5 inhibitors as first-line oral therapy.

Who Might Still Ask About Trazodone for ED?

Several groups of men bring up trazodone specifically. Men already on trazodone for depression may notice spontaneous erections and wonder whether the drug is treating their ED or causing them. Men who cannot tolerate PDE5 inhibitors due to the hemodynamic effects, specifically those on nitrates for chest pain, have no safe PDE5 option and may ask about alternatives. Men with antidepressant-induced sexual dysfunction sometimes seek trazodone specifically because SSRIs and SNRIs suppress sexual function, and trazodone does not share that mechanism; a randomized trial of trazodone in SSRI-induced sexual dysfunction (N=70) found partial reversal of anorgasmia and delayed ejaculation, though the erection findings were secondary endpoints only.

Men on nitrates are the clearest case where PDE5 inhibitors are contraindicated. For them, options include alprostadil (intraurethral or injectable), vacuum erection devices, penile prosthesis, or, with careful oversight, trazodone at low doses. The AUA guideline lists second-line and third-line options for men in whom PDE5 inhibitors are contraindicated. Trazodone does not appear in that guideline's algorithm, but it may be discussed as an adjunct by providers in refractory cases. A small case series suggested some benefit in men with organic ED refractory to standard therapy, though sample sizes preclude any firm conclusion.

The shared clinical principle across all five agents is that none of them creates desire. Sexual arousal must be present. A man whose ED has a predominantly psychogenic or relationship-based origin may respond to any pharmacological nudge, which is likely why the Costabile trazodone trial enrolled only psychogenic ED patients and still found a meaningful placebo response of 25%.

Dosing, Timing, and Practical Prescribing Notes

Sildenafil: Start at 50 mg fasted, 30 to 60 minutes before activity. Increase to 100 mg if inadequate response after 4 attempts. Reduce to 25 mg in men over 65 or with hepatic impairment. Sildenafil dosing per prescribing information.

Tadalafil on-demand: Start at 10 mg, taken at least 30 minutes before activity. Increase to 20 mg if needed. Daily dosing starts at 2.5 mg, titrated to 5 mg. Tadalafil dosing per prescribing information.

Vardenafil: 10 mg taken 25 to 60 minutes before activity. Adjust to 5 mg or 20 mg. The Staxyn ODT formulation is 10 mg; do not interchange mg-for-mg with the film-coated tablet without reassessing. Vardenafil dosing per prescribing information.

Avanafil: 100 mg is the recommended starting dose, taken 15 to 30 minutes before activity. Can lower to 50 mg or raise to 200 mg. Avanafil dosing per prescribing information.

Trazodone (off-label): Doses studied in ED range from 50 mg to 200 mg, taken 1 to 2 hours before activity. No standard protocol exists. Any man using trazodone off-label for ED should be counseled about the risk of priapism and instructed to seek emergency care if an erection persists beyond four hours. FDA trazodone prescribing information with priapism warning.

Men who have tried a single PDE5 inhibitor and report no response should be counseled on optimization: correct timing, adequate arousal before dosing, and at least 4, 6 attempts before declaring failure. A 2009 analysis found that roughly 40% of men who initially report PDE5 inhibitor failure succeed with counseling on proper use and optimal dosing. Optimization counseling outcomes from this multicenter study.

What Blood Tests and History Should Precede Any ED Prescription?

Erectile dysfunction is frequently a vascular sentinel event. A 2018 meta-analysis of 7 prospective studies (N=92,757) found that men with ED had a 44% higher risk of subsequent major adverse cardiovascular events compared to men without ED (HR 1.44 to 95% CI 1.27, 1.63). That meta-analysis on PubMed. Prescribing an ED medication without addressing the underlying vascular risk factors misses a critical clinical window.

Before prescribing any ED agent, HealthRX providers assess fasting glucose (or HbA1c), fasting lipid panel, blood pressure, and total and free testosterone. Hypogonadism suppresses sexual desire and impairs PDE5 inhibitor response; a total testosterone below 300 ng/dL on two morning samples meets the AUA threshold for evaluation. AUA testosterone deficiency guideline. Correcting hypogonadism with testosterone replacement therapy before or alongside PDE5 inhibitor use improves outcomes in hypogonadal men with ED. A randomized trial of testosterone plus sildenafil vs. sildenafil alone (N=140) in hypogonadal men with ED showed that the combination produced a 23% greater improvement in IIEF scores than sildenafil alone.

Trazodone adds another layer of complexity to this picture. Trazodone itself can lower blood pressure, and combining it with an alpha-blocker or antihypertensive agent may produce orthostatic hypotension. The same hemodynamic concern applies if a man ever moves from trazodone to a PDE5 inhibitor while on an alpha-blocker, the combination requires dose separation and careful blood pressure monitoring. Drug interaction data for trazodone and antihypertensives from the FDA label.